Both types of therapy have demonstrated efficacy in subsets of patients with certain tumor types, with TKIs exhibiting efficacy in, for example, NSCLC with EGFR-activating mutations (25), and anti-EGFR antibodies in tumor types such as metastatic CRC (mCRC) (9), and SCCHN (26). Here, EGFR is linked to non-small cell lung carcinoma.